Epidemiology and risks for infection following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy
- 48 Downloads
CRS-HIPEC is associated with improved cancer survival but an increased risk of infection.
Consecutive patients undergoing CRS-HIPEC between January 2016 and May 2018 were retrospectively reviewed. Malignancy type, comorbidities, perioperative risk factors and infectious complications were captured, using standardised definitions. Association between risk factors and infection outcomes was evaluated by logistic regression modelling.
One-hundred patients underwent CRS-HIPEC, predominantly for colorectal cancer and pseudomyxoma peritonei. Overall, 43 (43.0%) experienced an infectious complication, including infections at surgical site (27), respiratory tract (9), urinary tract (11), Clostridium difficile (2) and post-operative sepsis (15). In most, infection onset was within 7 days post-operatively. Median length of hospitalisation was 19 days for patients with infection, compared to 8 days for those without (p = 0.000). There were no deaths at 60 days. Of variables potentially associated with surgical site infection, small bowel resection (OR 4.01, 95% confidence interval [CI] 1.53–10.83; p = 0.005) and number of resected viscera (OR 1.41, 95% CI 1.00–1.98; p = 0.048) were significantly associated with infection.
We demonstrate a significant burden of early infective complications in patients undergoing CRS-HIPEC. Higher-risk subgroups, including those with small bowel resection and increased number of resected viscera, may benefit from enhanced monitoring.
KeywordsCRS-HIPEC Infection Surgical site infection
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Chua TC, Yan TD, Saxena A, Morris DL (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249(6):900–907CrossRefGoogle Scholar
- 2.Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D, French Surgical Association (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 116(24):5608–5618CrossRefGoogle Scholar
- 4.Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, van Ginkel R, Havenga K, Bremers AJ, de Wilt JH, te Velde EA, Verwaal VJ (2013) Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 20(13):4224–4230CrossRefGoogle Scholar
- 5.Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol : official journal of the American Society of Clinical Oncology. 21(20):3737–3743CrossRefGoogle Scholar
- 6.Pamela K, Matthias Z, Reinhold KR, Julia P, Peter M, Alexander P, et al. (2018) Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience in Austria. J Gastrointest Surg : official journal of the Society for Surgery of the Alimentary TractGoogle Scholar
- 7.Tan G, Chia C, Kumar M, Choo SP, Chia J, Tham CK, et al. (2016) 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group:1-7Google Scholar
- 9.Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA (2015) Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol 22(5):1673–1679CrossRefGoogle Scholar
- 11.Feldheiser A, Aziz O, Baldini G, Cox BP, Fearon KC, Feldman LS, Gan TJ, Kennedy RH, Ljungqvist O, Lobo DN, Miller T, Radtke FF, Ruiz Garces T, Schricker T, Scott MJ, Thacker JK, Ytrebø LM, Carli F (2016) Enhanced recovery after surgery (ERAS) for gastrointestinal surgery, part 2: consensus statement for anaesthesia practice. Acta Anaesthesiol Scand 60(3):289–334CrossRefGoogle Scholar
- 12.Scott MJ, Baldini G, Fearon KC, Feldheiser A, Feldman LS, Gan TJ, Ljungqvist O, Lobo DN, Rockall TA, Schricker T, Carli F (2015) Enhanced recovery after surgery (ERAS) for gastrointestinal surgery, part 1: pathophysiological considerations. Acta Anaesthesiol Scand 59(10):1212–1231CrossRefGoogle Scholar
- 18.Thursky K, Lingaratnam S, Jayarajan J, Haeusler GM, Teh B, Tew M, Venn G, Hiong A, Brown C, Leung V, Worth LJ, Dalziel K, Slavin MA (2018) Implementation of a whole of hospital sepsis clinical pathway in a cancer hospital: impact on sepsis management, outcomes and costs. BMJ Open Qual 7(3):e000355CrossRefGoogle Scholar
- 23.Dazza M, Schwarz L, Coget J, Frebourg N, Wood G, Huet E, Bridoux V, Veber B, Tuech JJ (2016) Does intraoperative systematic bacterial sampling during complete cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) influence postoperative treatment? A new predictive factor for postoperative abdominal infectious complications. World J Surg 40(12):3035–3043CrossRefGoogle Scholar
- 25.Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol : official journal of the American Society of Clinical Oncology 22(16):3284–3292CrossRefGoogle Scholar
- 30.Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, et al. (2017) The comprehensive complication index: a new measure of the burden of complications after hyperthermic intraperitoneal chemotherapy. Ann Surg OncolGoogle Scholar